Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 5/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | VNN1 | O95497 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.32 |
| ▸ | SORD | Q00796 | 2/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | TARDBP | Q13148 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21258918 | 0.83 | NPC1 (0.35) | PTPN11CHRNA7VNN1FFAR4HCRTR1 | |
| SCHEMBL21258934 | 0.78 | CKS1B (0.37) | PTPN11CHRNA7 | |
| SCHEMBL21258881 | 0.77 | VNN1 (0.33) | PTPN11VNN1LRRK2SORDTARDBP | |
| SCHEMBL21259003 | 0.76 | PTPN11 (0.36) | PTPN11VNN1LRRK2SORD | |
| SCHEMBL21258879 | 0.74 | KDM4E (0.53) | PTPN11LRRK2SORDHTR2C | |
| SCHEMBL23135163 | 0.73 | TARDBP (0.37) | PTPN11VNN1TARDBP | |
| SCHEMBL21259010 | 0.72 | PTPN11 (0.33) | PTPN11LRRK2SORDTARDBP | |
| SCHEMBL28705721 | 0.68 | MAOB (0.51) | CHRNA7SORD | |
| SCHEMBL31382372 | 0.64 | UBE2T (0.37) | VNN1LRRK2SORD | |
| SCHEMBL21258928 | 0.60 | CDK2 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087168-A1 | PROSTACYCLIN RECEPTOR AGONIST | MEDSHINE DISCOVERY INC. (CN) | 2021-03-25 | — | — | US | disclosed |
| EP-3750879-A1 | PROSTACYCLIN RECEPTOR AGONIST | Medshine Discovery Inc. (CN) | 2020-12-16 | — | — | EP | disclosed |
| WO-2019154363-A1 | PROSTACYCLIN RECEPTOR AGONIST | 南京明德新药研发有限公司 | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087168-A1 | PROSTACYCLIN RECEPTOR AGONIST | PTGIR, TBXA2R, PTGFR | PTPN11 2006/4885CHRNA7 450/4885VNN1 3468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.